http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1106432-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d1c3a385135699d6dfb7fe4c2d39fbf
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C251-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
filingDate 2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaac6f5ea68c1c003c4725c246faf224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04351b9ff86a5221ea40766657d19698
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b9110b481d45efb6b5faed95ed0446f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26672d36215cc9d40eff2c8a362398e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecb5d609354897df8f0f3c181a856a2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1adb99b21525fe0ae58260c77251bf15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1df2a76d35e33a708a3e2e5e07f6378b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3b3847e4c419f25bc215781876090b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65508af632da9f2979fe5487db31ccbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63b501977fb9b34bf8f5eea8cc932ccf
publicationDate 2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-PI1106432-A2
titleOfInvention aldimine-derived compounds, pharmaceutical compositions and use
abstract ALDIMINE DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE. The present invention comprises aldimine-derived compounds as well as pharmaceutical compositions containing such compounds and pharmaceutically acceptable excipients, as well as their use in the treatment of fungal infections of medical and / or veterinary importance. The aldimines and derivatives thereof have shown equal or better antifungal action. than commercially available medicines such as fluconazole. Because they are new drugs, the resistance of pathogens to them is greatly reduced. The synthesis of aldimines is carried out through a one-step process in which the reaction develops within two minutes and yields between 70-80%, which enables its large-scale production, as it is a fast and efficient process. compared to other available drugs.
priorityDate 2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505877
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425745069
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123139

Total number of triples: 26.